细胞外囊泡在肾脏病治疗中的研究进展

细胞外囊泡(extracellular vesicles, EVs)是细胞分泌的由脂质双分子层包绕形成的膜性囊泡,其内包含丰富的生物学信息,参与多种生理和病理过程。近年来,EVs在疾病治疗中也展现出了巨大应用前景,一方面来源于干细胞的EVs可以直接发挥治疗作用,另一方面EVs还可以作为一种天然的药物递送载体,为疾病的治疗提供新的给药策略。本文聚焦EVs在肾脏病治疗中的应用和研究进展。     

干细胞来源的胞外囊泡对T细胞的免疫调控作用

胞外囊泡（EVs）是细胞旁分泌产生的一种亚细胞成分,实质上是一组纳米级颗粒。它是双层膜结合型囊泡,内含蛋白质、核酸等活性成分。EVs在细胞间通过转移携带的信号分子而获得重要的地位。目前关于EVs在体外和体内的研究中对T细胞的调控能力引起了人们广泛的兴趣。在大多数研究中干细胞被报道能够抑制T细胞的增殖、活化和分化,在极少数研究中也发现干细胞具有增强T细胞免疫反应的作用。事实上所有的细胞类型均能释放EVs,包括干/祖/前体细胞。EVs被认为是细胞间交流的一种新机制,具有与干/祖细胞等亲代细胞相似的免疫调控作用。本综述是概述干/祖细胞来源的EVs对T细胞调控作用及可能的机制。     

综述与专论: 适配体功能化外泌体在肿瘤靶向治疗中的应用

传统的肿瘤治疗方法因缺乏足够的靶向性而会产生严重的毒副作用。外泌体（exosome）是一种天然的纳米囊泡,参与细胞间的信息传递,并且作为药物递送载体具有出色的性能优势,包括低免疫原性、低毒性和能够穿越天然屏障等特点。然而以外泌体为载体的药物递送系统的靶向能力仍有不足。适配体（aptamer）是一类化学合成的单链核酸分子,具有分子质量小、易于修饰和免疫原性低等特点,可作为亲和性配体与靶向分子特异性结合。通过在外泌体表面修饰适配体,药物可以被精确递送到肿瘤细胞发生部位,从而实现对肿瘤的靶向治疗,提高肿瘤治疗效果,减少毒副作用。本篇综述将重点讨论适配体功能化外泌体药物靶向递送系统在各种肿瘤治疗方面的应用,并对其未来的挑战和机遇进行阐述。     

外泌体在疾病诊断和药物递送系统中的应用研究进展

外泌体是直径为 30~100 nm 的内吞衍生囊泡,由多种活细胞分泌,含有大量的与其来源和功能密切相关的蛋白质、脂质和 RNA 分子,可以在细胞间传递。已有研究表明癌症患者血液中的外泌体浓度比正常人高,且其中包含癌症标志分子,因此其有潜力成为疾病诊 断的生物标志物。此外,作为一种天然的物质运输载体,外泌体已经被作为一种新型的药物递送系统,用于肿瘤及阿尔茨海默病等疾病的治疗。 对外泌体作为疾病诊断标记物以及药物递送载体的研究进展进行综述。     

肠道菌群来源细胞外囊泡在肝脏疾病中的作用研究进展

细胞外囊泡(extracellular vesicles, EVs)是一类具有脂质双分子层的膜性囊泡,可以被各种类型细胞分泌,是生物体通信的重要介质,参与原核生物和真核生物细胞之间的信号传输。在肠道微生态中,微生物-宿主的双向通信通常不需要细胞直接接触,微生物群来源EVs是这种“跨界”对话的关键参与者。肠-肝轴是连接肠道微生物与肝脏的桥梁,参与包含酒精性脂肪性肝病在内的多种肝脏疾病的发生与发展,近年研究发现肠道菌群来源的EVs在肝脏疾病的进程中具有重要的调控作用。本文概述了肠道菌群来源EVs的研究进展,特别是EVs的产生机制、包裹的内容物、在细菌-宿主互作以及在肝脏疾病中的作用。     

综述: 胞外囊泡表面糖缀合物研究进展

胞外囊泡(extracellular vesicles,EVs)是一类由细胞分泌到胞外的能够被受体细胞摄取的膜性囊泡小体,直径在20～ 1 000 nm．近年来,越来越多的研究者发现胞外囊泡在疾病诊断、预后评估以及药物递送等方面具有重要的生物学作用．胞外囊泡可以直接参与细胞间信息的传递以及物质的运输,其携带的核酸(mRNA,microRNA和lncRNA)和蛋白质可以影响受体细胞的生理状态．大量研究表明,胞外囊泡是被糖基化修饰的,胞外囊泡表面覆盖了大量的聚糖以及糖结合蛋白,而已知聚糖类物质在调控细胞黏附、细胞-细胞之间的信息传递、细胞和细胞外基质相互作用、免疫调节和肿瘤转移等方面发挥重要的作用．本文综述了近年来细胞外囊泡表面糖缀合物修饰的前沿研究,以期更好地理解聚糖在胞外囊泡的合成、释放以及运输过程及其生物学功能中的作用．     

新的药物传递系统:外泌体作为药物载体递送*

外泌体(exosomes)是细胞分泌的囊泡,在细胞与细胞之间通信中发挥重要作用。由于其固有的长距离通信能力和出色的生物相容性而具有很大的潜力作为药物递送载体,尤其适合递送蛋白质、核酸、基因治疗剂等治疗药物。许多研究表明外泌体可以有效地将许多不同种类的货物递送至靶细胞,因此,它们常被作为药物载体用于治疗。对外泌体作为药物递送系统中面临的外泌体分离,药物装载和靶向治疗应用的进展与挑战作一介绍,以期更好为外泌体药物递送系统开发提供新思路。     

新的药物传递系统:外泌体作为药物载体递送*

外泌体(exosomes)是细胞分泌的囊泡,在细胞与细胞之间通信中发挥重要作用。由于其固有的长距离通信能力和出色的生物相容性而具有很大的潜力作为药物递送载体,尤其适合递送蛋白质、核酸、基因治疗剂等治疗药物。许多研究表明外泌体可以有效地将许多不同种类的货物递送至靶细胞,因此,它们常被作为药物载体用于治疗。对外泌体作为药物递送系统中面临的外泌体分离,药物装载和靶向治疗应用的进展与挑战作一介绍,以期更好为外泌体药物递送系统开发提供新思路。     

内皮祖细胞来源胞外囊泡促进血管生成的研究进展

内皮祖细胞(endothelial progenitor cells,EPCs)是一种具备较强分化及增殖能力的细胞,并有良好的血管生成作用。目前研究表明EPCs旁分泌的胞外囊泡(extracellular vesicles,EVs)可独立作为一种生物活性物质在细胞间传递信息并参与血管生成的过程。EVs大致可以分成3类:包括凋亡小体(apoptosis body)、微泡(microvesicles)和外泌体(exosomes),分布于各种体液中,是蛋白质、脂质、核酸等分子的天然载体,通过生物体液循环可被局部或远处的靶细胞吸收,并传递囊泡内的物质。本综述主要对内皮祖细胞来源的微泡和外泌体的生物学特性,参与调节血管生成的机制,及在多种疾病诊疗中的临床应用前景展开讨论,以便于我们更好地理解内皮祖细胞来源的胞外囊泡的生物功能和治疗潜力。     

间充质干细胞来源细胞外囊泡对肺部疾病作用研究进展

细胞外囊泡(extracellular vesicles, EVs)是细胞自然分泌的脂质囊泡结构,在生理和病理过程中发挥信息交流作用。间充质干细胞(mesenchymal stromal cell, MSCs)是一种来源广泛的多能基质干细胞,其强大的再生潜能及免疫调节能力在肺部疾病的修复和治疗中显示出广阔前景。间充质干细胞来源细胞外囊泡(mesenchymal stromal cell extracellular vesicles, MSCs-EV)具有类似MSCs的功能特性,其携带的多种活性因子在肺部组织、肺微环境及肺部疾病中展现出良好治疗效果。主要总结了MSCs及MSCs-EV生物特性,深入讨论了MSCs-EV在肺部疾病中的作用机制及临床应用价值。     

Extracellular Vesicles in chondrogenesis and Cartilage regeneration

Extracellular vesicles (EVs), mainly exosomes and microvesicles, are bilayer lipids containing biologically active information, including nucleic acids and proteins. They are involved in cell communication and signalling, mediating many biological functions including cell growth, migration and proliferation. Recently, EVs have received great attention in the field of tissue engineering and regenerative medicine. Many in vivo and in vitro studies have attempted to evaluate the chondrogenesis potential of these microstructures and their roles in cartilage regeneration. EVs derived from mesenchymal stem cells (MSCs) or chondrocytes have been found to induce chondrocyte proliferation and chondrogenic differentiation of stem cells in vitro. Preclinical studies have shown that exosomes derived from MSCs have promising results in cartilage repair and in cell-free therapy of osteoarthritis. This review will focus on the in vitro and in vivo chondrogenesis and cartilage regeneration of EVs as well as their potential in the treatment of osteoarthritis.     

间充质干细胞来源外泌体在膝骨关节炎微环境中的作用

骨关节炎是一种涉及所有关节成分（包括关节软骨、软骨下骨、滑膜、韧带、关节囊和关节周围肌肉）的关节退行性疾病，会导致严重的残疾，其中最常见的是膝骨关节炎（knee osteoarthritis，KOA）。外泌体是一种由不同细胞分泌的直径为40~100 nm的胞外囊泡，可以传递DNA、微小RNA、mRNA、蛋白质等多种物质，并通过多种方式进行细胞间的信息传递和功能调节。间充质干细胞（mesenchymal stem cells，MSCs）可以从骨髓、脂肪、滑膜及外周血等组织分离，是一类具有多向分化潜能的祖细胞，以干细胞为基础的疗法可以修复软骨损伤，对抗KOA的发展，间充质干细胞能够分泌多种营养因子来调节受损的微环境，其中间充质干细胞来源的外泌体被认为在KOA炎症反应及软骨细胞代谢中发挥着重要的作用，其能够调节膝骨关节微环境中B细胞、T细胞、滑膜细胞、软骨细胞代谢及其细胞外基质的分解与合成平衡，维持软骨稳态。近期有多项研究表明，不同组织来源的间充质干细胞外泌体对骨关节炎均有明确的治疗作用，本文就MSCs来源的外泌体治疗KOA的具体机制进行综述，以期对干细胞治疗KOA提供理论依据。     

Emerging Significance and Therapeutic Potential of Extracellular vesicles

Extracellular vesicles (EVs), are membrane-bound vesicles that have many advantages over traditional nanocarriers for drug and gene delivery. Evidence from recent studies indicate that EVs have therapeutic capability with chemical or biological modification. Tumor-derived exosomes (TEXs) were used as a new type of antigens or tumor vaccines in anti-tumor immunotherapy. With superior characteristics, modified EVs were applied to loaded and delivered synthetic drugs, silencing RNA, and microRNA for treatment. Different surface functionalization strategies have been proposed to improve the therapeutic functions of EVs. Appropriately modified EVs for disease intervention provide new avenues for effective clinical treatment strategies. Therefore, this review aimed at elucidating the therapeutic functions of EVs to generate new ideas for treatment and to unlock their hidden potential in translational medicine.     

Tumor-derived extracellular vesicles: Potential tool for cancer diagnosis,prognosis, and therapy

Various types of cancer pose a notable threat to human health globally. To date, many researchers have undertaken the search for anticancer therapies. However, many anticancer therapeutic approaches accompany many undesirable hazards. In this respect, extracellular vesicles as a whole gained excessive attention from the research community owing to their remarkable potential for delivery of anticancer agents since they are involved in distal intercellular communication via biological cargoes. With the discovery of the fact that tumor cells discharge huge quantities of EVs, new insights have been developed in cancer diagnosis and treatment. Tumor-derived extracellular vesicles (TD-EVs) can be distinguished from the normal cell-derived EVs due to the presence of specific labels on their surface. TD-EVs carry specific oncogenic proteins and the nucleic acids on their surface membrane that participate in tumor progression. Moreover, the proportion of these nucleic acids and the protein greatly varies among malignant and healthy cell-derived EVs. The diagnostic potential of TD-EVs can be implied for the more precise and early-stage detection of cancer that was impossible in the past. This review examines the recent progress in prognostic, diagnostic, and therapeutic potential of the EVs derived from the tumor cells.     

Mesenchymal stem cell-derived extracellular vesicles as a new therapeutic strategy for ocular diseases

Mesenchymal stem cells (MSCs) have attracted considerable attention for their activity in the treatment of refractory visual disorders. Since MSCs were found to possess the beneficial effects by secreting paracrine factors rather than direct differentiation, MSC-derived extracellular vesicles (EVs) were widely studied in various disease models. MSCs generate abundant EVs, which act as important mediators by exchanging protein and genetic information between MSCs and target cells. It has been confirmed that MSC-derived EVs possess unique anti-inflammatory, anti-apoptotic, tissue repairing, neuroprotective, and immunomodulatory properties, similar to their parent cells. Upon intravitreal injection, MSC-derived EVs rapidly diffuse through the retina to alleviate retinal injury or inflammation. Due to possible risks associated with MSC transplantation, such as vitreous opacity and pathological proliferation, EVs appear to be a better choice for intravitreal injection. Small size EVs can pass through biological barriers easily and their contents can be modified genetically for optimal therapeutic effect. Hence, currently, they are also explored for the possibility of serving as drug delivery vehicles. In the current review, we describe the characteristics of MSC-derived EVs briefly, comprehensively summarize their biological functions in ocular diseases, and discuss their potential applications in clinical settings.     

The role of extracellular vesicles in endometrial receptivity and their potential in reproductive therapeutics and diagnosis

Extracellular vesicles (EVs) are small, nanometre sized, membrane-enclosed structures released by cells and are thought to be crucial in cellular communication. The cargo of these vesicles includes lipids, proteins, RNAs and DNA, and control various biological processes in their target tissues depending on the parental and receiver cell’s origin and phenotype. Recently data has accumulated in the role of EVs in embryo implantation and pregnancy, with EVs identified in the uterine cavity of women, sheep, cows, horses, and mice, in which they aid blastocyst and endometrial preparation for implantation. Herein is a critical review to decipher the role of extracellular vesicles in endometrial receptivity and their potential in reproductive therapies and diagnosis. The current knowledge of the function of embryo and endometrial derived EVs and their cargoes, with regards to their effect on implantation and receptivity are summarized and evaluated. The findings of the below review highlight that the combined knowledge on EVs deriving from the endometrium and embryo have the potential to be translated to various clinical applications including treatment, a diagnostic biomarker for diseases and a drug delivery tool to ultimately improve pregnancy rates.     

Extracellular vesicles: Emerged as a promising strategy for regenerative medicine

Cell transplantation therapy has certain limitations including immune rejection and limited cell viability, which seriously hinder the transformation of stem cell-based tissue regeneration into clinical practice. Extracellular vesicles (EVs) not only possess the advantages of its derived cells, but also can avoid the risks of cell transplantation. EVs are intelligent and controllable biomaterials that can participate in a variety of physiological and pathological activities, tissue repair and regeneration by transmitting a variety of biological signals, showing great potential in cell-free tissue regeneration. In this review, we summarized the origins and characteristics of EVs, introduced the pivotal role of EVs in diverse tissues regeneration, discussed the underlying mechanisms, prospects, and challenges of EVs. We also pointed out the problems that need to be solved, application directions, and prospects of EVs in the future and shed new light on the novel cell-free strategy for using EVs in the field of regenerative medicine.     

Human umbilical cord mesenchymal stem cell-derived extracellular vesicles: A novel therapeutic paradigm

Mesenchymal stem cells (MSCs) have been revealed to hold great potential for the development of new treatment approaches for various diseases. However, the clinical use of these cells is limited due to their tumorigenic effects. The therapeutic benefits of MSCs are largely dependent on paracrine factors including extracellular vesicles (EVs). EVs are nano-sized bilayer membrane structures containing lipids, microRNAs and proteins which play key roles in cell-to-cell communications. Because of their lower immunogenicity, tumorigenicity, and easier management, EVs have emerged as a new promising alternative to whole-cell therapy. Therefore, this paper reviews current preclinical studies on the use of EVs derived from human umbilical cord MSCs (hucMSCs) as a therapeutic approach in treatment of several diseases including neurological, cardiovascular, liver, kidney, and bone diseases as well as the cutaneous wound, inflammatory bowel disease, cancers, infertility, and other disorders.     

富血小板血浆注射治疗在膝骨关节炎中的应用进展

富血小板血浆(platelet-rich plasma，PRP)由于富含多种活性生长因子，能够刺激软骨细胞增殖，促进软骨前体细胞增殖、迁移、向软骨细胞分化，促进胶原蛋白合成以及抑制软骨的炎性反应和退变，提供有利于组织修复的内环境，延缓病情进展。近年来PRP注射治疗已成为治疗与骨关节炎(osteoarthritis，OA)相关疾病的新型选择，并且疗效显著。为了进一步提高其效用，PRP注射治疗不仅在关节腔内进行，还可在软骨下骨内进行注射。软骨下骨的病变会加速软骨损耗，故有必要将软骨下骨也当作OA众多发病机制和病理过程的关键因素之一。根据PRP的生物特效以及PRP注射治疗在膝骨关节炎(knee osteoarthritis，KOA)中应用的研究进展进行了综述，同时对软骨下骨内PRP注射治疗KOA的研究进行了展望，以期为KOA的治疗提供更加有效的方法。     

Exosome release and cargo in Down syndrome

Down syndrome (DS) is a multisystem disorder affecting 1 in 800 births worldwide. Advancing technology, medical treatment, and social intervention have dramatically increased life expectancy, yet there are many etiologies of this disorder that are in need of further research. The advent of the ability to capture extracellular vesicles (EVs) in blood from specific cell types allows for the investigation of novel intracellular processes. Exosomes are one type of EVs that have demonstrated great potential in uncovering new biomarkers of neurodegeneration and disease, and also that appear to be intricately involved in the transsynaptic spread of pathogenic factors underlying Alzheimer's disease and other neurological diseases. Exosomes are nanosized vesicles, generated in endosomal multivesicular bodies (MVBs) and secreted by most cells in the body. Since exosomes are important mediators of intercellular communication and genetic exchange, they have emerged as a major research focus and have revealed novel biological sequelae involved in conditions afflicting the DS population. This review summarizes current knowledge on exosome biology in individuals with DS, both early in life and in aging individuals. Collectively these studies have demonstrated that complex multicellular processes underlying DS etiologies may include abnormal formation and secretion of extracellular vesicles such as exosomes.